SUMO化通路抑制在急性髓系白血病中的治疗协同与免疫激活
本研究利用患者来源AML样本与临床前模型评估SUMO化通路抑制剂TAK-981的治疗及免疫调节作用。SAE1、SAE2、UBC9在新诊断AML中升高并与原始细胞比例正相关;TAK-981具抗白血病活性,与维奈克拉及吉瑞替尼协同,并在免疫健全模型中诱导CD8⁺T细胞、NK细胞扩增及颗粒酶B、IFN-γ、TNF-α持续升高。
要点
- SUMO通路组分SAE1、SAE2、UBC9在新诊断AML中高表达且与骨髓原始细胞比例正相关
- TAK-981与维奈克拉、吉瑞替尼在体外及离体样本中协同,异种移植中四周三药方案获持久疾病控制与生存获益
- TAK-981可重塑系统免疫,增加CD8⁺T细胞与NK细胞频率并持续升高颗粒酶B、IFN-γ、TNF-α
核心结论
- SUMO通路抑制TAK-981通过直接抗白血病作用与免疫重编程,有望作为组合策略提高AML治疗持久性并克服耐药。
研究设计与样本
- 研究采用患者来源AML样本与临床前模型评估TAK-981的治疗与免疫调节效应。
- 检测新诊断AML中SAE1、SAE2、UBC9表达并分析其与骨髓原始细胞负荷的相关性。
- 在体外与离体测试抗白血病活性及与维奈克拉、吉瑞替尼的药物相互作用,并在异种移植模型验证。
- 在免疫健全AML模型中通过免疫亚群与效应细胞因子/介质特征分析免疫重编程。
主要发现
- SAE1、SAE2、UBC9在初诊标本中显著高于缓解标本,并与原始细胞百分比正相关。
- TAK-981在体外和离体显示强效抗白血病活性,并与维奈克拉和吉瑞替尼协同。
- 异种移植中TAK-981增强两药疗效,四周三药方案产生持久疾病控制与更优生存获益且安全性良好。
- 免疫健全模型中TAK-981诱导系统免疫重塑,包括CD8⁺T细胞与NK细胞频率增加、记忆T细胞极化。
- TAK-981使颗粒酶B、IFN-γ、TNF-α持续升高。
关键数值与推荐
- SAE1、SAE2、UBC9在新诊断AML标本中显著高于缓解标本,且与原始细胞百分比正相关。
- TAK-981与维奈克拉及吉瑞替尼在体外和离体协同,异种移植中四周三药方案获持久疾病控制与生存获益。
- 免疫健全模型中CD8⁺T细胞与NK细胞频率增加,颗粒酶B、IFN-γ、TNF-α持续升高。
临床怎么用
- TAK-981联合维奈克拉或吉瑞替尼可能作为提高AML治疗持久性并克服耐药的候选组合策略。
- SUMO通路组分表达与原始细胞负荷相关,提示其作为疾病负荷相关标志物的潜在价值。
局限性
- 证据主要来自患者样本体外/离体实验与临床前模型,尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is a clinically aggressive malignancy with poor outcomes driven by frequent relapse and therapeutic resistance. Because the SUMOylation pathway regulates genome maintenance, transcription control, and immune evasion, it represents a promising therapeutic target in AML. We evaluated the therapeutic and immunomodulatory effects of TAK-981 using patient-derived AML samples and preclinical models. Expression of SUMO pathway components (SAE1, SAE2, and UBC9) was assessed in newly diagnosed AML and correlated with bone marrow blast burden. Anti-leukemic activity and drug interactions with venetoclax and gilteritinib were tested in vitro and ex vivo and validated in xenograft models, while immune reprogramming was characterized in immunocompetent AML models by profiling immune subsets and effector cytokine/mediator signatures. SAE1, SAE2, and UBC9 were significantly higher in bulk diagnostic specimens than in remission specimens and positively correlated with blast percentages. TAK-981 showed potent anti-leukemic activity and synergized with venetoclax and gilteritinib in vitro and ex vivo. In xenograft studies, TAK-981 enhanced the efficacy of both agents, and a four-week triplet regimen produced durable disease control and superior survival benefit with a favorable safety profile. In immunocompetent models, TAK-981 induced systemic immune remodeling, including increased CD8⁺ T-cell and NK-cell frequencies, memory T-cell polarization, and sustained elevation of granzyme B, IFN-γ, and TNF-α. These findings support SUMO pathway inhibition with TAK-981 as a promising combinatorial strategy to improve treatment durability and overcome resistance in AML through both direct anti-leukemic effects and immune reprogramming.
引用
- Son H, Kim BR, Choi M, et al. Therapeutic Synergy and Immune Activation by SUMOylation Pathway Inhibition in Acute Myeloid Leukemia. Blood Adv. 2026. PMID: 42962268. doi:10.1182/bloodadvances.2026020561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。